Nicolas

$IBRX ImmunityBio might be one of the few companies that could actually change the world. I’ll try to explain simply what they actually do and what makes them different. Here's what I found 🧵

Just started a position in $IBRX at $7.58. Planning to DCA over the next few weeks.

🚨 WHY IS $IBRX DUMPING -27% TODAY? It’s tanking on an FDA Warning Letter (issued March 13). NOT a rejection, NOT a safety issue, NOT a clinical hold. Straight to the point 🧵 👉What does the FDA letter actually say? It calls out a TV ad + a podcast featuring Dr. Soon-Shiong (The Sean Spicer Show, Jan 19) for misleading claims: Anktiva “cures cancer,” “treats all cancers,” and even “prevents cancer.” Classic slap on the wrist for aggressive promotional hype (they already got 2 Untitled Letters before). Company has 15 business days to fix it. Is it serious? NO. ANKTIVA is still fully approved, selling, and expanding: ✅ Saudi Arabia launch underway ✅ Approved in Macau + 33 countries ✅ NCCN guidelines just added it (yesterday) ✅ sBLA resubmission for papillary NMIBC in progress Fundamentals 100% intact. Pure biotech volatility: big rally → profit-taking + FDA marketing slap = overreaction. Shorts are piling in, but the long-term thesis is alive and well. Dip buy under $7 or waiting for more blood? 🔥

Sivers is transitioning from an engineering-driven business to a scalable, product-led semiconductor company. 📈 Pipeline growing (+64%) ⚙️ Product mix improving (+90%) 🚗 LiDAR ramp coming 🧠 AI datacenter exposure 💰 Model pointing to high margins Not financial advice.

This slide from $SIVE says it all. 2 axes: ➡️ Revenue growth (CAGR) ➡️Product gross margins Peers like $AVGO $AMD $ALAB $LITE $ADI $MRVL $MTSI sit across the matrix with premium valuations. Today, $SIVE sits in the “valuation zone” (mid-low). But the CEO made it clear: They are now entering the execution zone driven by the shift to product (photonics). The goal is obvious: Move to the top-right quadrant 📈 → high growth → high margins That’s where 20–40x multiples live. The CEO is basically saying: We’re executing towards a re-rating 🔥

$SIVE is getting attention on Twitter 🔥 I posted a thread this weekend, but I’ve gathered more information to complement it. Let’s go 🧵

2026 was supposed to be: → Rate cuts → AI printing money → Soft landing → Multiple expansion → Risk-on everywhere And then...

🚨 BANK OF AMERICA INITIATES COVERAGE ON $NBIS (Nebius) with BUY + $150 PT (31% upside from current ~$115 levels). But what really matters is NOT just the conservative PT. BofA’s report is much deeper and more bullish than it looks at first glance. 👇 Key takeaway from BofA analyst Tal Liani: Nebius builds and operates large-scale data centers that let companies like Meta and Microsoft train and run AI models without having to spend a single dollar on their own infrastructure. “Nebius is an emerging leader in global AI compute” ➡️ this is a massive opportunity in a market that is exploding. Their platform is purpose-built for GPU-dense and distributed workloads, with hyperscaler clients already locked in. The total addressable market for IaaS + AI IaaS is heading toward $419 billion by 2028. Nebius is already showing strong numbers: revenue +351% YoY and 68.6% gross margin. 🔥Catalysts nobody can ignore: ➡️ Massive ~$27B 5-year contract with Meta (includes huge NVIDIA Vera Rubin deployments starting 2027) ➡️ Strategic $2B investment from NVIDIA to scale its AI cloud. These deals fund the capex and validate the tech. Very low risk of dilution or high debt. Street comparison (so you see BofA is actually the most conservative): DA Davidson → raised PT to $200 (post-Meta deal) BWS Financial → also to $200 Citigroup → Buy + $169 Compass Point → Buy $150 (reaffirmed) Consensus across 12-13 analysts: average PT ~$158-167 (+38-45% upside). BOFA just confirmed what many of us already saw: $NBIS is a pure, high-quality play in AI Infrastructure-as-a-Service, with locked-in hyperscaler contracts that pay upfront and premium gross margins. This isn’t hype. These are real contracts + real growth + brutal positioning.

@alc2022 @BastianelliLore I think in a short future Europe goverments will talk about global taxes. If you are spanish, you will pay taxes even if you are in other country. I made a mistake, my broker account is spanish. Something tells me that @alc2022 didnt make the same mistake.

@BastianelliLore Just take fly somewhere else and buy a new laptop

few understand the joy of both staring at your screen for hours and enjoying the mediterranean lifestyle modern men need both

@MegaAlphaSeeker 🎯

@snmart Guess how many tokens and how much it will cost if you rely solely on Claude to execute repeated tasks on enterprise level. Not mentioning accuracy and accountability.

Claude’s new “computer use” feature is not an immediate death blow to $PATH, but it is another clear signal of where automation is going. The bearish case is obvious: if frontier models can directly use software interfaces, part of traditional rule-based RPA gets commoditized over time. But here’s the nuance most people are missing: $PATH already uses Claude. $PATH integrated Anthropic’s models into products like Autopilot and Clipboard AI, and also offers direct Claude connectors inside its platform. So this is not simply “Claude vs $PATH.” In some ways, it’s Claude inside $PATH. That’s why I don’t think this is an immediate “ $PATH is dead” moment. Large enterprises do not just pay for a model that can click buttons. They pay for governance, orchestration, integrations, auditability, reliability, and compliance at scale.

@_jaydeepkarale Thats the $PATH thesis

90% companies dont allow this btw

@BinhTrans I agree. The key point for me is that $PATH is still one of the best enterprise options. Claude is powerful at the user level but companies need compliance, reliability, and trust.

@snmart Claude doesnt solve the biggest problem, what happens if Claude gets banned? For Uipath, this isnt a problem as you can use whichever LLM you want inside their system. Why would anyone want to bind themselves with one model? Only small business can afford that.

@aleabitoreddit @xreaptor Good morning Serenity. Whats your background? I love your analysis

@xreaptor One @aleabitoreddit analysis a day keeps the doctor away

Studying @aleabitoreddit is the way to success.

Good morning, deep divers. There are plenty of opportunities right now. Any stock on your watchlist? 👀